These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 16290987

  • 1. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine.
    Petronio AS, De Carlo M, Ciabatti N, Amoroso G, Limbruno U, Palagi C, Di Bello V, Romano MF, Mariani M.
    Am Heart J; 2005 Nov; 150(5):1015. PubMed ID: 16290987
    [Abstract] [Full Text] [Related]

  • 2. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
    Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP.
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
    [Abstract] [Full Text] [Related]

  • 3. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial).
    Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP.
    J Am Coll Cardiol; 2007 Apr 10; 49(14):1517-24. PubMed ID: 17418289
    [Abstract] [Full Text] [Related]

  • 4. Prospective randomised study to evaluate effectiveness of distal embolic protection compared to abciximab administration in reduction of microembolic complications of primary coronary angioplasty.
    Ochała A, Smolka G, Wojakowski W, Gabrylewicz B, Garbocz P, Tendera M.
    Kardiol Pol; 2007 Jun 10; 65(6):672-80; discussion 681-3. PubMed ID: 17629829
    [Abstract] [Full Text] [Related]

  • 5. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial.
    Ince H, Petzsch M, Kleine HD, Eckard H, Rehders T, Burska D, Kische S, Freund M, Nienaber CA.
    Circulation; 2005 Aug 30; 112(9 Suppl):I73-80. PubMed ID: 16159869
    [Abstract] [Full Text] [Related]

  • 6. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL, Kampinga MA, Wieringa WG, Fokkema ML, Nijsten MW, Hillege HL, van den Heuvel AF, Tan ES, Pundziute G, van der Werf R, Hoseyni Guyomi S, van der Horst IC, Zijlstra F, de Smet BJ.
    Circulation; 2010 Dec 21; 122(25):2709-17. PubMed ID: 21098442
    [Abstract] [Full Text] [Related]

  • 7. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P, ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up.
    N Engl J Med; 2001 Jun 21; 344(25):1895-903. PubMed ID: 11419426
    [Abstract] [Full Text] [Related]

  • 8. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
    Wöhrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M, Hombach V, Höher M.
    Circulation; 2003 Apr 15; 107(14):1840-3. PubMed ID: 12682003
    [Abstract] [Full Text] [Related]

  • 9. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW, CADILLAC Investigators.
    Circulation; 2003 Sep 16; 108(11):1316-23. PubMed ID: 12939213
    [Abstract] [Full Text] [Related]

  • 10. Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).
    Taglieri N, Saia F, Guiducci V, Tondi S, Conrotto F, Marrozzini C, Rocchi G, Biagini E, Reggiani ML, Giacometti P, Piovaccari G, Manari A, Marzocchi A, FATA Trial Investigators.
    Am J Cardiol; 2009 Mar 15; 103(6):785-90. PubMed ID: 19268732
    [Abstract] [Full Text] [Related]

  • 11. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
    Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, Stone GW, CADILLAC Investigators.
    Am J Cardiol; 2004 Oct 15; 94(8):983-8. PubMed ID: 15476608
    [Abstract] [Full Text] [Related]

  • 12. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial.
    Gabriel HM, Oliveira JA, da Silva PC, da Costa JM, da Cunha JA.
    Catheter Cardiovasc Interv; 2006 Aug 15; 68(2):218-24. PubMed ID: 16817177
    [Abstract] [Full Text] [Related]

  • 13. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
    Bertrand OF, Rodés-Cabau J, Larose E, Rinfret S, Gaudreault V, Proulx G, Barbeau G, Déry JP, Gleeton O, Manh-Nguyen C, Noël B, Roy L, Costerousse O, De Larochellière R, EArly Discharge after Transradial Stenting of CoronarY Arteries in Acute Myocardial Infarction (EASY-MI) Study Investigators.
    Am J Cardiol; 2010 Jun 01; 105(11):1520-7. PubMed ID: 20494655
    [Abstract] [Full Text] [Related]

  • 14. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators.
    N Engl J Med; 2002 Mar 28; 346(13):957-66. PubMed ID: 11919304
    [Abstract] [Full Text] [Related]

  • 15. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A, Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators.
    Circulation; 2004 Dec 14; 110(24):3627-35. PubMed ID: 15531766
    [Abstract] [Full Text] [Related]

  • 16. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Grygier M, Araszkiewicz A, Lesiak M, Janus M, Kowal J, Skorupski W, Pyda M, Mitkowski P, Grajek S.
    Am J Cardiol; 2011 Apr 15; 107(8):1131-5. PubMed ID: 21310372
    [Abstract] [Full Text] [Related]

  • 17. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
    Hassan AK, Liem SS, van der Kley F, Bergheanu SC, Wolterbeek R, Bosch J, Bootsma M, Zeppenfeld K, van der Laarse A, Atsma DE, Jukema JW, Schalij MJ.
    Catheter Cardiovasc Interv; 2009 Aug 01; 74(2):335-43. PubMed ID: 19642182
    [Abstract] [Full Text] [Related]

  • 18. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G.
    Circulation; 2008 Jul 01; 118(1):49-57. PubMed ID: 18559698
    [Abstract] [Full Text] [Related]

  • 19. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G, Stone GW, Cox DA, Stuckey T, Tcheng JE, Turco M, Musumeci G, Griffin JJ, Lansky AJ, Mehran R, Grines CL, Garcia E.
    Circulation; 2004 Sep 21; 110(12):1598-604. PubMed ID: 15353506
    [Abstract] [Full Text] [Related]

  • 20. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction.
    Zhang H, Tian NL, Hu ZY, Wang F, Chen L, Zhang YJ, Chen SL.
    Chin Med J (Engl); 2012 May 21; 125(10):1713-9. PubMed ID: 22800889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.